C&D Derives Relentless Optimism From Value/Premium Product Mix
This article was originally published in The Tan Sheet
Executive Summary
Church & Dwight's unflagging confidence and steadfast performance is attributable in part to its wide mix of products, CEO James Craigie suggests
You may also be interested in...
Church & Dwight Raises Guidance, Marketing Spend For 2009
Church & Dwight's increased spending on core premium brands in the face of the recession is paying off for the Arm & Hammer marketer, which is raising its full-year earnings-per-share guidance for the second time this year
Conference Presentations In Brief
Prestige seeks innovations for focus brands: Rather than wait for the next Allergen Block to come from an entrepreneurial inventor, Prestige Brands shifts to an active approach to finding breakthrough innovations. At the William Blair & Co. Growth Stock Conference June 9 in Chicago, Prestige CEO Mark Pettie explained the firm is moving away from depending on ideas from "opportunistic sources," and instead is building "standing relationships with technology houses with specific purposes." The firm then will apply the innovations to its focus products, including Chloraseptic treatment for sore throat, Little Remedies and Clear Eyes. Pettie referred to Allergen Block, a drug-free nasal gel, as the paradigm of a "fully differentiated technology" compared to other products in its segment. Irvington, N.Y.-based Prestige additionally is driving growth by prioritizing its focus brands, penetrating further into the Canadian market and shifting toward a direct-selling model with its retail customers (1"The Tan Sheet" March 16, 2009, p. 9). Pettie added the company soon will begin weighing possible business moves following a "self-imposed moratorium" on mergers and acquisitions
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC